Date Filed | Type | Description |
04/03/2023 |
4
| Ragosa Mark (CFO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.
Txns:
| Granted 42,050 options to buy
@ $10.76, valued at
$452.5k
Granted 7,000 options to buy
@ $0 |
|
03/20/2023 |
4
| Ragosa Mark (CFO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.
Txns:
| Paid exercise price by delivering 256 shares
@ $11.46, valued at
$2.9k
Paid exercise price by delivering 634 shares
@ $11.12, valued at
$7.1k
Exercised 872 options to buy
@ $0 Exercised 2,158 options to buy
@ $0 |
|
09/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/11/2022 |
4
| Ragosa Mark (CFO) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.
Txns:
| Granted 64,660 options to buy
@ $11.1, valued at
$717.7k
Granted 10,777 options to buy
@ $0 |
|
03/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/23/2020 |
3
| Ragosa Mark (Interim CFO) has filed a Form 3 on Kiniksa Pharmaceuticals, Ltd. |